Total Payments
$1.5M
2024 Payments
$119,790
Companies
64
Transactions
2,547
Medicare Patients
7,698
Medicare Billing
$712,144
Payment Breakdown by Category
Other$844,874 (57.1%)
Research$331,719 (22.4%)
Consulting$185,747 (12.6%)
Travel$61,173 (4.1%)
Food & Beverage$56,077 (3.8%)
Education$398.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750,914 | 266 | 50.7% |
| Unspecified | $331,719 | 198 | 22.4% |
| Consulting Fee | $185,747 | 61 | 12.6% |
| Honoraria | $79,260 | 32 | 5.4% |
| Travel and Lodging | $61,173 | 303 | 4.1% |
| Food and Beverage | $56,077 | 1,667 | 3.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,700 | 6 | 1.0% |
| Education | $398.40 | 14 | 0.0% |
Payments by Type
General
$1.1M
2,349 transactions
Research
$331,719
198 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $385,501 | 564 | $0 (2024) |
| Ichnos Sciences Inc. | $164,118 | 61 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $119,738 | 116 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $86,853 | 88 | $0 (2019) |
| GlaxoSmithKline, LLC. | $86,630 | 60 | $0 (2024) |
| Janssen Biotech, Inc. | $80,425 | 254 | $0 (2024) |
| LEO Pharma Inc. | $65,447 | 92 | $0 (2024) |
| PFIZER INC. | $64,840 | 180 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $57,471 | 116 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $54,171 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119,790 | 348 | ABBVIE INC. ($36,256) |
| 2023 | $140,856 | 297 | Janssen Biotech, Inc. ($26,558) |
| 2022 | $178,146 | 316 | ABBVIE INC. ($66,412) |
| 2021 | $173,078 | 256 | Ichnos Sciences Inc. ($39,547) |
| 2020 | $198,981 | 199 | Ichnos Sciences Inc. ($100,184) |
| 2019 | $241,435 | 338 | AbbVie, Inc. ($81,602) |
| 2018 | $190,867 | 412 | AbbVie, Inc. ($59,441) |
| 2017 | $236,838 | 381 | AbbVie, Inc. ($78,417) |
All Payment Transactions
2,547 individual payment records from CMS Open Payments — Page 1 of 102
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $2.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Dermatology | ||||||
| 12/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $6.38 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $110.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $67.77 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $47.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Immunology | ||||||
| 12/08/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $126.06 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: DERMATOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Immunology | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: VACCINES | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GBR830-204 | Ichnos Sciences Inc. | $139,731 | 58 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $78,434 | 64 |
| PICATO FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM IN IMMUNOCOMPROMISED PATIENTS | LEO Pharma Inc. | $37,292 | 5 |
| ISB830-204 | Ichnos Sciences Inc. | $24,386 | 3 |
| A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa | SANOFI US SERVICES INC. | $10,166 | 5 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $8,419 | 24 |
| A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | SANOFI US SERVICES INC. | $7,647 | 8 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $4,417 | 1 |
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | Almirall LLC | $3,250 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,388 | 5 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,210 | 3 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AT 16 WEEKS OF TREATMENT COMPARED TO USTEKINUMAB AND TO ASSESS LONG TERM SAFETY TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Novartis Pharmaceuticals Corporation | $1,928 | 1 |
| Publication support research related | Novartis Pharma AG | $1,567 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | Regeneron Pharmaceuticals, Inc. | $1,174 | 2 |
| A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | Celgene Corporation | $1,144 | 1 |
| PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $1,014 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | SANOFI-AVENTIS U.S. LLC | $1,002 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $579.04 | 2 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $505.00 | 1 |
| ADP2b | SANOFI-AVENTIS U.S. LLC | $472.43 | 1 |
| CC-10004-SPSO-001 - A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) | Celgene Corporation | $442.00 | 1 |
| JAK INHIBITOR DERM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $208.36 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $66.91 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,037 | 3,191 | $726,374 | $230,171 |
| 2022 | 16 | 2,023 | 3,258 | $486,806 | $163,346 |
| 2021 | 21 | 2,344 | 3,825 | $573,041 | $215,859 |
| 2020 | 15 | 1,294 | 2,027 | $156,975 | $102,768 |
Total Patients
7,698
Total Services
12,301
Medicare Billing
$712,144
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 454 | 668 | $118,757 | $41,857 | 35.2% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 56 | 80 | $110,251 | $38,896 | 35.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 223 | 274 | $63,435 | $22,382 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 153 | 197 | $49,419 | $17,160 | 34.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 183 | 214 | $61,471 | $13,890 | 22.6% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 24 | 40 | $33,172 | $13,394 | 40.4% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 20 | 26 | $34,128 | $12,695 | 37.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 178 | 178 | $41,004 | $12,508 | 30.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 191 | 259 | $36,309 | $9,956 | 27.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 61 | 72 | $23,736 | $9,176 | 38.7% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 34 | 42 | $40,725 | $7,734 | 19.0% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 58 | 67 | $17,666 | $6,269 | 35.5% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 22 | 28 | $24,302 | $5,030 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $13,379 | $4,279 | 32.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 143 | 736 | $25,079 | $3,813 | 15.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 55 | 80 | $8,339 | $3,162 | 37.9% |
| 67850 | Destruction of growth of eyelid margin, 1.0 cm or less | Office | 2023 | 12 | 14 | $5,922 | $2,004 | 33.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 43 | 45 | $5,115 | $1,863 | 36.4% |
| 10061 | Complicated or multiple drainage of skin abscess | Office | 2023 | 12 | 12 | $5,616 | $1,713 | 30.5% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 21 | 32 | $3,868 | $1,151 | 29.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 18 | 18 | $2,629 | $804.18 | 30.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 38 | $1,931 | $410.20 | 21.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 20 | 31 | $119.82 | $25.56 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 457 | 678 | $97,031 | $41,864 | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 215 | 297 | $62,370 | $26,313 | 42.2% |
About Stephen Tyring, MD PHD
Stephen Tyring, MD PHD is a Dermatology healthcare provider based in Webster, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245227263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Stephen Tyring, MD PHD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $119,790 received in 2024. These payments were reported across 2,547 transactions from 64 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($750,914).
As a Medicare-enrolled provider, Tyring has provided services to 7,698 Medicare beneficiaries, totaling 12,301 services with total Medicare billing of $712,144. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Webster, TX
- Active Since 10/04/2005
- Last Updated 11/14/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1245227263
Products in Payments
- Humira (Biological) $168,615
- TREMFYA (Drug) $117,448
- GBR830-204 (Drug) $100,184
- SHINGRIX (Biological) $84,830
- SKYRIZI (Biological) $81,507
- RINVOQ (Biological) $77,931
- Tremfya (Drug) $42,759
- DUPIXENT DUPILUMAB INJECTION (Biological) $41,724
- PICATO (Drug) $39,692
- Skyrizi (Biological) $38,149
- COSENTYX (Biological) $36,819
- ILUMYA (Biological) $35,714
- EUCRISA (Drug) $26,057
- STELARA (Biological) $23,821
- AMZEEQ (Drug) $21,532
- VTAMA (Drug) $20,573
- DUPIXENT (Drug) $18,242
- DUPIXENT (Biological) $17,861
- SPEVIGO (Drug) $14,567
- LITFULO (Drug) $14,324
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Webster
Dr. Karan Sra, Md, MD
Dermatology — Payments: $218,130
Dermatology $218,130
Dr. Patricia Lee, M.d, M.D
Dermatology — Payments: $102,356
Dermatology $102,356
Dr. Narin Apisarnthanarax, M.d, M.D
Dermatology — Payments: $26,107
Dermatology $26,107
Dr. Alexander Marzuka, M.d, M.D
Dermatology — Payments: $13,457
Dermatology $13,457
Dr. Janice Chang, M.d, M.D
Dermatology — Payments: $3,397
Dermatology $3,397
Terry Williams, M.d, M.D
Dermatology — Payments: $2,720
Dermatology $2,720